BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21570540)

  • 1. [Situation of supply and boom of PET imaging: what is the future for technetium-99m in nuclear medicine?].
    Maia S; Ayachi Hatit N; Paycha F
    Ann Pharm Fr; 2011 May; 69(3):155-64. PubMed ID: 21570540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-animal preclinical nuclear medicine instrumentation and methodology.
    Rowland DJ; Cherry SR
    Semin Nucl Med; 2008 May; 38(3):209-22. PubMed ID: 18396180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites.
    Eckelman WC; Jones AG; Duatti A; Reba RC
    Drug Discov Today; 2013 Oct; 18(19-20):984-91. PubMed ID: 23806975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future of nuclear medicine: SPECT versus PET.
    Gholamrezanejhad A; Mirpour S; Mariani G
    J Nucl Med; 2009 Jul; 50(7):16N-18N. PubMed ID: 19652221
    [No Abstract]   [Full Text] [Related]  

  • 5. The future of SPECT in a time of PET.
    Jansen FP; Vanderheyden JL
    Nucl Med Biol; 2007 Oct; 34(7):733-5. PubMed ID: 17921025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is hybridic positron emission tomography/computerized tomography the only option? The future of nuclear medicine and molecular imaging.
    Grammaticos P; Zerva C; Asteriadis I; Trontzos C; Hatziioannou K
    Hell J Nucl Med; 2007; 10(2):74-6. PubMed ID: 17684579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in nuclear cardiology.
    Gutte H; Leth Petersen C; Kjaer A; Hesse B
    Panminerva Med; 2008 Jun; 50(2):105-18. PubMed ID: 18607334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 99m-Technetium carbohydrate conjugates as potential agents in molecular imaging.
    Bowen ML; Orvig C
    Chem Commun (Camb); 2008 Nov; (41):5077-91. PubMed ID: 18956031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear medicine in myeloma: the state of the science and emerging trends.
    Sood A; Revannasiddaiah S; Kumar R
    Hell J Nucl Med; 2011; 14(1):2-5. PubMed ID: 21512656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The uncertain path to the future of imaging biomarkers.
    Nunn AD
    Q J Nucl Med Mol Imaging; 2007 Jun; 51(2):96-8. PubMed ID: 17420711
    [No Abstract]   [Full Text] [Related]  

  • 12. Nuclear medicine 2020.
    Strauss HW
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):1-3. PubMed ID: 16557198
    [No Abstract]   [Full Text] [Related]  

  • 13. Nuclear medicine applications in molecular imaging: 2007 update.
    Blankenberg FG; Strauss HW
    Q J Nucl Med Mol Imaging; 2007 Jun; 51(2):99-110. PubMed ID: 17420712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET versus SPECT: strengths, limitations and challenges.
    Rahmim A; Zaidi H
    Nucl Med Commun; 2008 Mar; 29(3):193-207. PubMed ID: 18349789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How many PET tracers do we need?
    Schwaiger M; Wester HJ
    J Nucl Med; 2011 Dec; 52 Suppl 2():36S-41S. PubMed ID: 22144553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future of nuclear medicine--impact of new radiopharmaceuticals and of alternative methods such as nuclear magnetic resonance.
    Pfannenstiel P; Rinck PA
    Nuklearmedizin; 1984 Dec; 23(6):273-6. PubMed ID: 6335745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained availability of 99mTc: possible paths forward.
    Pillai MR; Dash A; Knapp FF
    J Nucl Med; 2013 Feb; 54(2):313-23. PubMed ID: 23255729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questionnaire survey of hospitals in Saitama Prefecture regarding the shortage of 99mTc-labeled radiopharmaceuticals and 99Mo/99mTc generators.
    Kosuda S; Tomita H; Hayashi K; Kita T; Koike K; Arai T
    Ann Nucl Med; 2010 May; 24(4):319-23. PubMed ID: 20204551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol.
    Kühl HP; Lipke CS; Krombach GA; Katoh M; Battenberg TF; Nowak B; Heussen N; Buecker A; Schaefer WM
    Eur Heart J; 2006 Apr; 27(7):846-53. PubMed ID: 16434414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phantom assessment of portable imaging and radio-guided surgery systems with technetium-99m and fluorine-18.
    Krohn T; Verburg FA; Brockmann H; Winz OH; Mottaghy FM; Behrendt FF
    Nucl Med Commun; 2012 May; 33(5):452-8. PubMed ID: 22466010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.